Table 1.
Variable | Estimate ($US) | Source |
---|---|---|
Vaccine acquisition | ||
TIV | 9.45 | CDC [39] |
aTIV | 13.65 | Assumption |
QIV | 13.65 | Assumption |
Vaccine administration | ||
All ages | 21.00 | Prosser [41] |
Antiviral cost | ||
All ages | 92.35 | Talbird et al. [42] |
Medical consultation | ||
All ages | 98.79 | Talbird et al. [42] |
Complications | ||
Pneumonia without hospitalization | ||
All ages | 206 | Talbird et al. [42] |
Pneumonia with hospitalization | ||
0–19 | 5513 | Talbird et al. [42] |
20–64 | 14,828 | |
≥65 | 14,137 | |
Bronchitis without hospitalization | ||
All ages | 221 | Talbird et al. [42] |
Bronchitis with hospitalization | ||
0–19 | 3906 | Talbird et al. [42] |
20–64 | 7449 | |
≥65 | 8834 | |
Other respiratory without hospitalization | ||
All ages | 221 | Talbird et al. [42] |
Other respiratory with hospitalization | ||
0–19 | 3906 | Talbird et al. [42] |
20–64 | 7449 | |
≥65 | 8834 | |
CVD without hospitalization | ||
All ages | 2711 | American Heart Association [43] |
CVD with hospitalization | ||
All ages | 6017 | American Heart Association [43] |
Otitis media | ||
All ages | 224 | Talbird et al. [42] |
Lost productivity costs | ||
Without complications | ||
0–3 | 145 | Molinari et al. [27]; case not medically attended |
4–6 | 97 | |
7–19 | 73 | |
20–64 | 68 | |
65+ | 145 | |
Extra loss due to minor complications | ||
0–3 | 183 | Molinari et al. [27]; weighted average of non-high-risk and high-risk outpatient visit |
4–6 | 209 | |
7–9 | 191 | |
10–19 | 186 | |
20–49 | 167 | |
50–64 | 386 | |
65+ | 832 | |
Extra loss due to serious complications (pneumonia, bronchitis, CVD) | ||
0–3 | 1333 | Molinari et al. [27]; weighted average of non-high-risk and high-risk outpatient visit |
4–6 | 1576 | |
7–9 | 1520 | |
10–19 | 1603 | |
20–49 | 1934 | |
50–64 | 2411 | |
65+ | 2256 | |
Otitis media | ||
All ages | 0 | Assumed no additional days lost |
aTIV adjuvanted trivalent inactivated influenza vaccine, CDC Centers For Disease Control And Prevention, CVD cardiovascular disease, QIV Quadrivalent inactivated influenza vaccine, TIV trivalent inactivated influenza vaccine